Acasti Pharma Inc Share Price Toronto S.E.
Equities
APO
CA00430K1057
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- CAD | - |
12/02 | Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
07/02 | Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.44Cr 2.53Cr 210.39Cr |
---|---|---|---|---|---|
Net income 2024 * | -1.8Cr -1.32Cr -110.08Cr | Net income 2025 * | -2.3Cr -1.69Cr -140.66Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.89
x | P/E ratio 2025 * |
-2.43
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.98% |
Latest transcript on Acasti Pharma Inc
Managers | Title | Age | Since |
---|---|---|---|
Prashant Kohli
CEO | Chief Executive Officer | 52 | 01/21/01 |
Director of Finance/CFO | 52 | 05/01 | |
Carrie D'Andrea
CTO | Chief Tech/Sci/R&D Officer | 52 | 08/23/08 |
Members of the board | Title | Age | Since |
---|---|---|---|
A. Davis
BRD | Director/Board Member | 57 | 10/23/10 |
Director/Board Member | - | 10/23/10 | |
Santosh Kottayil
BRD | Director/Board Member | - | 10/23/10 |
1st Jan change | Capi. | |
---|---|---|
+32.09% | 69TCr | |
+29.39% | 58TCr | |
-1.34% | 37TCr | |
+20.34% | 33TCr | |
+7.39% | 29TCr | |
+14.25% | 24TCr | |
-3.03% | 21TCr | |
+10.02% | 21TCr | |
+8.49% | 17TCr |
- Stock Market
- Equities
- ACST Stock
- APO Stock